The Therapeutic Effects of EFNB2-Fc in a Cell Model of Kawasaki Disease
Open Access
- 28 March 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (4) , 500
Abstract
The EphrinB2/EphB4 signaling pathway involves the regulation of vascular morphogenesis and angiogenesis. However, little is known about EphrinB2/EphB4 in the pathogenesis of Kawasaki disease (KD) and coronary artery aneurysm formation. Hence, this study aimed to explore the role of EphrinB2/EphB4 and the potential therapeutic effect of EphrinB2-Fc in the coronary arterial endothelial injury of KD. The levels of EphB4 were compared between KD patients and healthy children. Human coronary artery endothelial cells (HCAECs) were stimulated with sera from acute KD patients to establish the KD cell model. The overexpression of EphB4 or treatment with EphrinB2-Fc was found to intervene in the cell model. The cell migration, angiogenesis, and proliferation ability were assessed, and the expression of inflammation-related factors was measured. Our study showed that EphB4 showed low expression in both KD patients and the cell model of KD. The EphB4 protein levels in the CECs of CAA+ KD patients were much lower than those in healthy children. EphrinB2-Fc treatment of KD sera-activated HCAECs suppressed cell proliferation, reduced the expression of inflammation-related factors (such as IL-6 and P-selectin), and elevated cell angiogenesis ability. The results reveal that EphrinB2-Fc has a protective function in endothelial cells and has promising clinical applications for protecting vascular endothelium in patients with KD.Keywords
Funding Information
- National Natural Science Foundation of China (81970434)
This publication has 38 references indexed in Scilit:
- S100A12 on Circulating Endothelial Cells Surface in Children With Kawasaki DiseasePediatric Research, 2010
- Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesisNature, 2010
- Therapeutic interference with EphrinB2 signalling inhibits oxygen-induced angioproliferative retinopathyActa Ophthalmologica, 2009
- Activation of the receptor EphB4 by its specific ligand ephrin B2 in human osteoarthritic subchondral bone osteoblastsArthritis & Rheumatism, 2008
- PSGL-1–mediated activation of EphB4 increases the proangiogenic potential of endothelial progenitor cellsJournal of Clinical Investigation, 2007
- Bidirectional ephrinB2-EphB4 signaling controls bone homeostasisCell Metabolism, 2006
- Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cellsJournal of Cell Science, 2003
- Vascular Endothelial Growth Factor Induction of the Angiogenic Phenotype Requires Ras ActivationJournal of Biological Chemistry, 2001
- A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving MethotrexateNew England Journal of Medicine, 1999
- Designing CD4 immunoadhesins for AIDS therapyNature, 1989